New eyedrops aim to soothe dry, irritated eyes
NCT ID NCT05586152
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental eyedrop called INV-102 in 84 adults with moderate dry eye disease. The study had two parts: first, checking safety at different doses, and second, seeing if the drops improve eye dryness symptoms after two weeks. Participants used the drops or a placebo (vehicle) twice daily. The goal is to find a new option for people whose dry eyes aren't helped by current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INV-102 ophthalmic solution (eyedrops)
What this could lead to
If successful, this could lead to a new eyedrop treatment that eases dryness and discomfort in people with moderate dry eye disease.
What could go wrong
This is an early first-in-human study with only 84 participants and short 2-week dosing. The treatment may not prove effective or safe in larger, longer trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
iuvo BioScience
Rush, New York, 14543, United States